Aldeyra Therapeutics Inc (ALDX)

$3.48

+0.08

(+2.5%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Aldeyra Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.2% return, outperforming this stock by 132.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.2% return, outperforming this stock by 313.2%

Performance

  • $3.39
    $3.55
    $3.48
    downward going graph

    2.59%

    Downside

    Day's Volatility :4.51%

    Upside

    1.97%

    downward going graph
  • $1.42
    $8.54
    $3.48
    downward going graph

    59.2%

    Downside

    52 Weeks Volatility :83.37%

    Upside

    59.25%

    downward going graph

Returns

PeriodAldeyra Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
17.07%
0.7%
0.0%
6 Months
1.34%
8.4%
0.0%
1 Year
-56.19%
10.5%
0.0%
3 Years
-71.52%
17.1%
-23.0%

Highlights

Market Capitalization
205.9M
Book Value
$1.91
Earnings Per Share (EPS)
-0.51
PEG Ratio
0.0
Wall Street Target Price
9.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-14.29%
Return On Equity TTM
-23.94%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-35.1M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.18
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Aldeyra Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
11
11
Hold
1
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 165.8%

Current $3.48
Target $9.25

Technicals Summary

Sell

Neutral

Buy

Aldeyra Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
-12.27%
1.34%
-56.19%
-71.52%
-52.08%
Moderna, Inc.
Moderna, Inc.
-17.71%
41.64%
11.55%
-39.28%
857.26%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.07%
24.05%
34.11%
95.48%
226.11%
Novo Nordisk A/s
Novo Nordisk A/s
5.19%
37.27%
76.22%
243.21%
449.78%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
NA
NA
0.0
-0.18
-0.24
-0.14
NA
1.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.68
30.68
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.23
49.23
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.3
30.3
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc
Buy
$199.0M
-52.08%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.1B
857.26%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.5B
226.11%
30.68
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$629.2B
449.78%
49.23
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
158.93%
30.3
39.46%

Institutional Holdings

  • Perceptive Advisors LLC

    14.46%
  • Knoll Capital Management LP

    9.22%
  • Vanguard Group Inc

    6.51%
  • BlackRock Inc

    5.57%
  • Kennedy Capital Management Inc

    2.22%
  • Geode Capital Management, LLC

    1.73%

Company Information

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise

Organization
Aldeyra Therapeutics Inc
Employees
10
CEO
Dr. Todd C. Brady M.D., Ph.D.
Industry
Health Technology

FAQs